Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $6

ImmunityBio Inc Ordinary Shares +0.63% Pre

ImmunityBio Inc Ordinary Shares

IBRX

6.40

6.40

+0.63%

0.00% Pre

Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ: IBRX) with a Neutral and raises the price target from $5 to $6.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via